SCHEDULE: Anson Funds Discloses 0.1% Stake in Transcode Therapeutics
Beneficial Ownership Disclosure
Anson Funds Management LP and related entities reported a passive 0.1% beneficial ownership stake in Transcode Therapeutics, Inc. as of June 30, 2025.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam collectively reported beneficial ownership of 27,125 shares of Transcode Therapeutics, Inc. Common Stock.
- This aggregate amount represents 0.1% of the outstanding class of Common Stock.
- The percentage is calculated based on 23,341,336 shares of Subordinate Voting Shares outstanding as of May 12, 2025 (per the Issuer's Form 10-Q) plus the 27,125 shares receivable upon exercise of warrants held by the reporting persons.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of passive beneficial ownership and does not contain information that would indicate positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of passive beneficial ownership by an investment firm and its principals, providing transparency on their holdings in a publicly traded biotechnology company. It does not provide insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Provides transparency regarding a minor passive ownership stake by an investment group, indicating a small institutional presence.
Key Dates
| Date | Description |
|---|---|
| 2025-05-12 | Date of Issuer's Quarterly Report on Form 10-Q, reporting 23,341,336 shares of Subordinate Voting Shares issued and outstanding. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-08-14 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Transcode Therapeutics, Anson Funds, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.